Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer

Authors: Martin Loos, Dennis M Hedderich, Malte Ottenhausen, Nathalia A Giese, Melanie Laschinger, Irene Esposito, Jörg Kleeff, Helmut Friess

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Costimulatory signaling has been implicated as a potential regulator of antitumor immunity in various human cancers. In contrast to the negative prognostic value of aberrant B7-H1 expression by pancreatic cancer cells, the role of B7-H3 is still unknown. Therefore, we investigated the expression pattern and clinical significance of B7-H3 expression in human pancreatic cancer.

Methods

B7-H3 expression was evaluated by immunohistochemistry in 68 patients with pancreatic cancer who underwent surgical tumor resection. Expression data was correlated with clinicopathologic features and with the number of tumor-infiltrating T cells.

Results

B7-H3 expression was significantly upregulated in pancreatic cancer compared to normal pancreas (p < 0.05). In 60 of 68 examined tumors B7-H3 protein was detectable in pancreatic cancer cells. Patients with high tumor B7-H3 levels had a significantly better postoperative prognosis than patients with low tumor B7-H3 levels (p = 0.0067). Furthermore, tumor B7-H3 expression significantly correlated with the number of tumor-infiltrating CD8+ T cells (p = 0.018).

Conclusion

We demonstrate for the first time that B7-H3 is abundantly expressed in pancreatic cancer and that tumor-associated B7-H3 expression significantly correlates with prolonged postoperative survival. Our findings suggest that B7-H3 might play an important role as a potential stimulator of antitumor immune response in pancreatic cancer.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 2008, 58 (2): 71-96. 10.3322/CA.2007.0010.CrossRefPubMed
2.
Kleeff J, Michalski C, Friess H, Buchler MW: Pancreatic cancer: from bench to 5-year survival. Pancreas. 2006, 33 (2): 111-118. 10.1097/01.mpa.0000229010.62538.f2.CrossRefPubMed
3.
Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW: Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004, 91 (5): 586-594. 10.1002/bjs.4484.CrossRefPubMed
4.
Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002, 8 (8): 793-800.PubMed
5.
Gajewski TF, Meng Y, Harlin H: Immune suppression in the tumor microenvironment. J Immunother. 2006, 29 (3): 233-240. 10.1097/01.cji.0000199193.29048.56.CrossRefPubMed
6.
Laheru D, Jaffee EM: Immunotherapy for pancreatic cancer - science driving clinical progress. Nat Rev Cancer. 2005, 5 (6): 459-467. 10.1038/nrc1630.CrossRefPubMed
7.
Greenwald RJ, Freeman GJ, Sharpe AH: The B7 family revisited. Annu Rev Immunol. 2005, 23: 515-548. 10.1146/annurev.immunol.23.021704.115611.CrossRefPubMed
8.
Krummel MF, Allison JP: CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med. 1996, 183 (6): 2533-2540. 10.1084/jem.183.6.2533.CrossRefPubMed
9.
Dong H, Zhu G, Tamada K, Chen L: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999, 5 (12): 1365-1369. 10.1038/70932.CrossRefPubMed
10.
Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, Chapoval AI, Flies DB, Bajorath J, Chen L: B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity. 2003, 18 (6): 849-861. 10.1016/S1074-7613(03)00152-3.CrossRefPubMed
11.
Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M: B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004, 10 (15): 5094-5100. 10.1158/1078-0432.CCR-04-0428.CrossRefPubMed
12.
Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, et al: Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007, 13 (7): 2151-2157. 10.1158/1078-0432.CCR-06-2746.CrossRefPubMed
13.
Loos M, Giese NA, Kleeff J, Giese T, Gaida MM, Bergmann F, Laschinger M, M WB, Friess H: Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Lett. 2008, 268 (1): 98-109. 10.1016/j.canlet.2008.03.056.CrossRefPubMed
14.
Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, et al: Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005, 11 (8): 2947-2953. 10.1158/1078-0432.CCR-04-1469.CrossRefPubMed
15.
Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, et al: Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006, 66 (7): 3381-3385. 10.1158/0008-5472.CAN-05-4303.CrossRefPubMed
16.
Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S: Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother. 2007, 56 (8): 1173-1182. 10.1007/s00262-006-0266-z.CrossRefPubMed
17.
Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K, et al: B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2001, 2 (3): 269-274. 10.1038/85339.CrossRefPubMed
18.
Suh WK, Gajewska BU, Okada H, Gronski MA, Bertram EM, Dawicki W, Duncan GS, Bukczynski J, Plyte S, Elia A, et al: The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol. 2003, 4 (9): 899-906. 10.1038/ni967.CrossRefPubMed
19.
Luo L, Chapoval AI, Flies DB, Zhu G, Hirano F, Wang S, Lau JS, Dong H, Tamada K, Flies AS, et al: B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J Immunol. 2004, 173 (9): 5445-5450.CrossRefPubMed
20.
Lupu CM, Eisenbach C, Lupu AD, Kuefner MA, Hoyler B, Stremmel W, Encke J: Adenoviral B7-H3 therapy induces tumor specific immune responses and reduces secondary metastasis in a murine model of colon cancer. Oncol Rep. 2007, 18 (3): 745-748.PubMed
21.
Sun X, Vale M, Leung E, Kanwar JR, Gupta R, Krissansen GW: Mouse B7-H3 induces antitumor immunity. Gene Ther. 2003, 10 (20): 1728-1734. 10.1038/sj.gt.3302070.CrossRefPubMed
22.
Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK, Wang X: B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer. 2006, 53 (2): 143-151. 10.1016/j.lungcan.2006.05.012.CrossRefPubMed
23.
Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP: B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA. 2007, 104 (49): 19458-19463. 10.1073/pnas.0709802104.CrossRefPubMedPubMedCentral
24.
Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, Krambeck AE, McKenney ME, Karnes RJ, Blute ML, et al: B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 2007, 67 (16): 7893-7900. 10.1158/0008-5472.CAN-07-1068.CrossRefPubMed
25.
Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Buchler MW, Giese NA, Friess H: Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene. 2005, 24 (27): 4421-4432. 10.1038/sj.onc.1208642.CrossRefPubMed
26.
Wang L, Fraser CC, Kikly K, Wells AD, Han R, Coyle AJ, Chen L, Hancock WW: B7-H3 promotes acute and chronic allograft rejection. Eur J Immunol. 2005, 35 (2): 428-438. 10.1002/eji.200425518.CrossRefPubMed
27.
Wu CP, Jiang JT, Tan M, Zhu YB, Ji M, Xu KF, Zhao JM, Zhang GB, Zhang XG: Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J Gastroenterol. 2006, 12 (3): 457-459.CrossRefPubMedPubMedCentral
28.
Prasad DV, Nguyen T, Li Z, Yang Y, Duong J, Wang Y, Dong C: Murine B7-H3 is a negative regulator of T cells. J Immunol. 2004, 173 (4): 2500-2506.CrossRefPubMed
29.
Ling V, Wu PW, Spaulding V, Kieleczawa J, Luxenberg D, Carreno BM, Collins M: Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss. Genomics. 2003, 82 (3): 365-377. 10.1016/S0888-7543(03)00126-5.CrossRefPubMed
30.
Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, et al: Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 2008, 14 (16): 5150-5157. 10.1158/1078-0432.CCR-08-0536.CrossRefPubMedPubMedCentral
31.
Hashiguchi M, Kobori H, Ritprajak P, Kamimura Y, Kozono H, Azuma M: Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc Natl Acad Sci USA. 2008, 105 (30): 10495-10500. 10.1073/pnas.0802423105.CrossRefPubMedPubMedCentral
32.
Kalvakolanu DV, Borden EC: An overview of the interferon system: signal transduction and mechanisms of action. Cancer Invest. 1996, 14 (1): 25-53. 10.3109/07357909609018435.CrossRefPubMed
33.
Bui JD, Carayannopoulos LN, Lanier LL, Yokoyama WM, Schreiber RD: IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J Immunol. 2006, 176 (2): 905-913.CrossRefPubMed
34.
Chang CJ, Chen YH, Huang KW, Cheng HW, Chan SF, Tai KF, Hwang LH: Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors. Hepatology. 2007, 45 (3): 746-754. 10.1002/hep.21560.CrossRefPubMed
Metadata
Title
Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer
Authors
Martin Loos
Dennis M Hedderich
Malte Ottenhausen
Nathalia A Giese
Melanie Laschinger
Irene Esposito
Jörg Kleeff
Helmut Friess
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-463

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue

Research article

DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells

Research article

Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells

Research article

A role of BRCA1 and BRCA2germline mutations in breast cancer susceptibility within Sardinian population

Research article

Regulation of HSP27 on NF-κB pathway activation may be involved in metastatic hepatocellular carcinoma cells apoptosis

Research article

Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer

Research article

Vasohibin inhibits angiogenic sprouting in vitro and supports vascular maturation processes in vivo
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits